On Wednesday June 5th, Skye Bioscience's CSO Chris Twitty will present an overview of the company and its programs in obesity and glaucoma at the Jefferies Global Healthcare Conference 2024. You can listen to the webcast here: https://lnkd.in/g86ERASA
Skye Bioscience Inc.’s Post
More Relevant Posts
-
https://lnkd.in/dEg7uNSz Revolutionizing Healthcare: The Vitro Diagnostics Market is set to grow at a robust CAGR of 4.90%, reaching nearly US$103.37 Bn by 2029. 🌐🔬 Embracing test-tube experiments, the market thrives on combating chronic diseases, personalized medicine, and the rise of private diagnostic centers. 💉🌟 #MAXIMIZEMARKETRESEARCH #VitroDiagnostics #HealthcareInnovation #MedicalResearch #DiagnosticsMarket
To view or add a comment, sign in
-
-
Klarity Patient Transfer System for Brachytherapy
👉 𝐄𝐥𝐞𝐯𝐚𝐭𝐢𝐧𝐠 𝐏𝐚𝐭𝐢𝐞𝐧𝐭 𝐂𝐚𝐫𝐞 𝐰𝐢𝐭𝐡 𝐊𝐥𝐚𝐫𝐢𝐭𝐲'𝐬 𝐂𝐮𝐬𝐭𝐨𝐦𝐢𝐳𝐞𝐝 𝐏𝐚𝐭𝐢𝐞𝐧𝐭 𝐓𝐫𝐚𝐧𝐬𝐟𝐞𝐫 𝐒𝐲𝐬𝐭𝐞𝐦 𝐟𝐨𝐫 𝐁𝐫𝐚𝐜𝐡𝐲𝐭𝐡𝐞𝐫𝐚𝐩𝐲 Klarity's Patient Transfer System for brachytherapy now features a personalized design with monitoring devices and compact oxygen tanks. This ensures efficient vital sign monitoring and respiratory support during treatment. The feedback from our esteemed partner, Guangzhou Concord Cancer Center (GCCC) notes, "Klarity's system has significantly improved patient care, allowing for easy oxygen access in preparation, scanning, and treatment rooms." At Klarity, We are committed to advancing safety and quality in health care. Discover our innovations at Klarity website:https://lnkd.in/g5GFMCN
To view or add a comment, sign in
-
-
Join Bloomberg Intelligence for a monthly series where we discuss the latest on the forefront of healthcare. The inaugural webinar will focus on obesity, the potential size of the obesity market in-light of recent developments in the space as well as key takeaways from our Bloomberg Intelligence Obesity Survey. We'll also discuss broadening access and Medicare inclusion looking at prescriber hurdles and other factors that could influence the market size. #obesity #melanoma #oncology #healthcare #pharma
To view or add a comment, sign in
-
Insights on future directions for T1D therapies from experts in the islet biology and T1D field.
Just published: Islet Cells in T1D: from recent advances to novel therapies – a symposium-based roadmap for future research. Huge thanks to all speakers, contributors, organisers and or course our sponsors JDRF International and Diabetes UK, who made this symposium and article possible. Available to read open access here: https://lnkd.in/eWA-b7vH
To view or add a comment, sign in
-
-
The International Society on Thrombosis and Haemostasis (ISTH) WorldThrombosisDay Steering Committee's latest research, "Availability of medical and endovascular therapies for venous thromboembolism," is a groundbreaking effort to shed light on the discrepancies in global VTE therapy access. This comprehensive information will be pivotal in addressing healthcare shortcomings worldwide. Explore the findings in Journal of Thrombosis and Haemostasis (JTH): https://bit.ly/45znS25 #Thrombosis #GlobalHealthcare #WTDay23 #ISTH
To view or add a comment, sign in
-
Exciting news in the world of Cardio-Renal-Metabolic research! A recent clinical trial has shown promising results for a new treatment approach combining an aldosterone synthase inhibitor with a well-known SGLT2 inhibitor. This innovative combination has demonstrated a significant reduction in albuminuria, a critical marker of kidney damage, by up to 39.5% compared to placebo. These findings offer potential for additive benefits in kidney health while possibly reducing the risks associated with hyperkalemia, a common issue in existing therapies. With over a billion people globally affected by cardio-renal-metabolic conditions, the implications of these results are profound, potentially easing the burden on healthcare systems worldwide. The ongoing research is set to continue with a large-scale Phase III trial aimed at further investigating the efficacy and safety of this treatment combination. This milestone highlights the ongoing commitment of the scientific community to advancing healthcare through innovative research, aiming to enhance patient outcomes in the fight against interconnected diseases. #CardioRenalMetabolic #HealthcareInnovation #KidneyHealth #ClinicalTrials #BoehringerIngelheim
To view or add a comment, sign in
-
-
The closing session of #IPPC2024 moderated by Tomasz Kluszczynski emphasised the need for a consistent approach to immunoglobulin (IgG) use in Europe. Normal Polyvalent Immunoglobulins are a preferred or the only therapeutic option for many severe and/or potentially fatal diseases and conditions. But the increasing medical need for IgGs driven, among others, by better diagnostics and new indications, underscores the urgency to ensure optimal use. As Marek Migdal stated, "medical knowledge is changing. We must look for new indications and uses for the benefit of patients." Immunoglobulin use varies between countries. Although clear criteria for its use are important, the high need for immunoglobulins is not met by plasma collection. Johan Prevot highlighted that “patients will benefit from more regionally balanced plasma collection.” The Green Paper proposed a framework with three dimensions: level of unmet medical need, added therapeutic value, and quality of evidence. Daniela Philadelphy pointed out an important challenge: "In rare diseases, it's always good to get robust data, but it's sometimes not feasible. " A big thanks to Tomasz Kluszczynski, Johan Prevot, Silvia Sánchez-Ramón, Isabelle Durand-Zaleski, Marek Migdal and Daniela Philadelphy for this important discussion. #PlasmaProteins #PatientCare #DonorHealth #EUNeedsMorePlasma #SoHORegulation
To view or add a comment, sign in
-
📊Our new research indicates that physical activity in COPD is significantly enhanced through pharmacological therapy and behaviour modification interventions. On the contrary, the effect of exercise training on physical activity is not significant or consistent. 📌This is the first meta-analysis providing an estimation of pharmacological treatment effects on steps/day in patients with COPD. 🔍The study also highlights the requirement for reliable, sensitive, and innovative digital mobility outcomes (DMOs). These are necessary to track post-intervention effects by capturing the whole spectrum of mobility. Recommendations for future studies include: · drug-specific MCIDs anchored against disease-specific clinical constructs · assessing the convergent validity of DMOs. ⬇ https://lnkd.in/dmwpdXPt Mobilise-D Emily Hume Nikolaos Chynkiamis M.Sc., Ph.D. Ashley Polhemus Christopher Buckley @Henrik Watz Thierry Troosters IOANNIS VOGIATZIS
To view or add a comment, sign in
-
-
🏥Explore the next evolution in assessing liver health with OWLiver, an advanced, non-invasive assessment that utilizes metabolomic technology to evaluate liver function through the analysis of 39 distinct lipids.🧬 📊 Designed for precise detection across all harmful stages of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), OWLiver offers healthcare providers a dependable resource. It enables the monitoring of disease progression, ensuring meticulous attention to patient health 🩺. 🔍 This novel method marks a considerable advancement in the field of liver disease diagnosis, emphasizing patient ease while maintaining diagnostic precision. Lead the way in healthcare with OWLiver, merging the forefront of scientific innovation with clinical performance.
To view or add a comment, sign in
-